Trials
ANNEXA-I
In adult patients with acute major bleeding (including ICH) associated with recent use of a factor Xa inhibitor, does andexanet alfa, compared with usual care, result in better hemostatic efficacy and improved clinical outcomes?
In adult patients with acute major bleeding (including ICH) associated with recent use of a factor Xa inhibitor, does andexanet alfa, compared with usual care, result in better hemostatic efficacy and improved clinical outcomes?